GHRP-2 vs GHRP-6
How they differ
- FDA status, the same for both (Not FDA-approved). GHRP-2: No FDA approval reported; on FDA’s compounding safety-risk list (category 2).1 GHRP-6: No FDA approval reported; on FDA’s compounding safety-risk list (category 2).1
- Kinds of studies cited. GHRP-2: smaller controlled human trials. GHRP-6: limited human data. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | GHRP-2 | GHRP-6 |
|---|---|---|
| What it is | A synthetic hexapeptide amide (D-Ala-D-2-naphthylalanine-Ala-Trp-D-Phe-Lys-NH2), also recorded as pralmorelin and KP-102, according to FDA’s substance registry.2 | A synthetic hexapeptide amide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), also recorded as hexapeptide-2 and SK&F-110679, according to FDA’s substance registry.3 |
| FDA status | Not FDA-approved No FDA approval reported; on FDA’s compounding safety-risk list (category 2)1 No FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-2 in category 2 under its interim policy for outsourcing facilities, and its 503A nominations list, updated May 14, 2026, places it in category 3.1,4 | Not FDA-approved No FDA approval reported; on FDA’s compounding safety-risk list (category 2)1 No FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-6 in category 2 under its interim policy for outsourcing facilities, for substances that may present significant safety risks.1 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.5 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-2 is not among them.5,6 | Not among the six peptides the policy lists.5 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-6 is not among them.5,6 |
| FDA compounding safety-risk page | Listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-2 in category 2 under the interim policy for outsourcing facilities (section 503B) for certain routes since September 29, 2023, citing possible immune reactions from aggregation and impurities.1 | Listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-6 in category 2 under the interim policy for outsourcing facilities (section 503B) since September 29, 2023, citing possible immune reactions from aggregation and impurities.1 |
| Kinds of studies cited | Smaller controlled human trials
|
|
| Records collected | 0 ClinicalTrials.gov records and 21 PubMed records collected | 0 ClinicalTrials.gov records and 25 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2Pralmorelin (GHRP-2) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 3GHRP-6 (hexapeptide-2) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 4Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 5HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 6Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 7Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake (2006) · PMID 16861611 ↗
Obesity · Official source · Source checked November 16, 2026
- 8A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency (2007) · PMID 17609397 ↗
European Journal of Endocrinology · Official source · Source checked November 16, 2026
- 9Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers (2013) · PMID 23099431 ↗
European Journal of Pharmaceutical Sciences · Official source · Source checked November 15, 2026